: 2 3
While using Semaglutide GLP-1 , some people may experience mild side effects, such as nausea or stomach discomfort, particularly when starting the treatment
Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: insights from the SUSTAIN 17 trials
The danger zone begins when reported purity does not match actual purity, or when impurities include potentially harmful synthesis byproducts rather than benign truncated sequences
Dose spacing: Under medical supervision only, some patients stretch their medication by extending the time between doses
One potential mechanism is thought to involve activation of the central nervous system, with the area postrema (AP) and nucleus of the solitary tract (NTS) and the intermediolateral nucleus (IML) of the spinal cord similarly activated by administration of GLP-1RA 29,30